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EP-2012  
Are there differences in quality prostate indicators among 
9-Gy vs 15-Gy HDR brachytherapy boost? 
R. Tortosa1, P. Soler
1Hospital IMED Elche, Radiation Oncology, Elche Alicante, 
Spain 
1, N. Chinillach1, C. Ruiz1, M. Vila1, M. 
Sanchez1 
 
Purpose or Objective: The dose coverage in patients 
diagnosed with high risk prostate adenocarcinoma with 
seminal vesicles affection don´t suppose any problem in dose 
escalation with HDR Brachytherapy. But we wonder if the 
quality prostate implant indicators will show any differences 
between standard patients (15-Gy HDR) and those with 
seminal vesicles affection(9-Gy HDR). To evaluate it, a 
multivariate analysis has been performed in our Radiation 
Oncology Department 
 
Material and Methods: 120 patients with high risk prostate 
adenocarcinoma were selected for the study and divided into 
two groups. The treatment schedule was external beam 
radiotherapy plus high dose rate brachytherapy as a boost:  
- Group A: 9-Gy boost - T3b high grade (seminal vesicles 
affection) 46-Gy to pelvic areas, up to 60-Gy in prostate and 
seminal vesicles (2-Gy per fraction) daily and 9-Gy HDR to 
prostatic gland and 1-2cm. of proximal seminal vesicles.  
- Group B: 15-Gy boost – High grade (no seminal vesicles 
affection)46-Gy to pelvic areas (2-Gy per fraction) daily 
treatment and 15-Gy HDR to prostatic gland.  
Volumetric Modulated Arc Therapy (VMAT) was the selected 
technique for external radiotherapy delivered in a Varian 
DHX Clinac (Varian, Palo Alto, Ca.) with Millennium 120-MLC. 
Brachytherapy was performed with VariSource iX afterloader 
(Varian, Palo Alto, Ca.). The aim is to demonstrate whether 
there are any differences in both groups for dose 
homogeneity index (DHI) and homogeneity index (HI). A 
multivariate analysis was developed using as variables three 
of prostate (PTV volume, D90 , D100), two of urethra (Dmax, 
D10) and two of rectum (Dmax , D10). 
 
Results: The multivariate analysis for both groups shows a p-
value of 0.452 to obtain the probability for DHI > 0,75 and a 
p-value of 0.897 to obtain a probability for HI>0.70. In Figure 




Conclusion: According to dose homogeneity, the analysis 
states that there were no significant differences for both 
studied groups. These results suggest the possibility of 
increasing the boost dose in T3b patients 
 
EP-2013  
Single fraction HDR BT boost using ultrasound plng for 
prostate cancer: dosimetrics and toxicity 
M. Barkati
1Centre Hospitalier de l’Université de Montréal, Radiation 
Oncology, Montréal, Canada 
1, O. Lauche1, D. Taussky1, C. Ménard1, G. Delouya1 
 
Purpose or Objective: To validate the feasibility of a single-
fraction High Dose Rate Brachytherapy (HDRBT) Boost for 
prostate cancer using real-time Transrectal Ultrasound 
(TRUS) based planning. 
 
Material and Methods: From August 2012 to September 2015, 
113 patients underwent a single-fraction HDRBT boost of 15 
Gy using real-time TRUS based planning. External beam 
radiation therapy (EBRT) (37.5 Gy/15f or 44Gy/22f or 
45Gy/25f) was performed before (30%) or after (70%) HDRBT 
boost. We analyzed prostate, urethra and rectum dosimetrics 
data. Genito-Urinary (GU) and Gastro-Intestinal (GI) toxicity 
were assessed 4 and 12 months after the end of combined 
treatment using the International Prostate Symptom Score 
Scale (IPSS) and the Common Terminology Criteria for 
Adverse Events (CTCAE) v3.0.  
 
Results: Prostate D90 between 105% and 115% was achieved 
for 99% of patients, prostate V150 ≤ 40% for 99%, prostate 
V200 < 11% for 96%, urethra D10 <120% for 99%, urethra 
V125=0% for 100% and rectum V75<1cc for 95% of patients. 
Median IPSS score was 4 at the baseline and didn’t change at 
4 and 12 months after combined treatment. No patients 
developed ≥ grade 2 GI toxicity. With a median follow-up of 
10 months, only two patients experienced biochemical 
failure. Cumulative percentage of patients with PSA ≤ 1 at 4 
and 18 months was respectively 47% and 74 %. 
 
Conclusion: Single-fraction HDRBT boost of 15 Gy using real-
time TRUS based planning in combination with EBRT is a safe 
treatment with promising results. A longer follow-up is 
needed to assess long-term outcome and toxicities 
 




Retrospective analysis of interstitial brachytherapy in 
gynecological and digestive tumours 
C. De la Pinta Alonso
1Ramon y Cajal Hospital, Radiation Oncology, Madrid, Spain 
1, E. Fernandez-Lizarbe1, A. Montero 
Luis2, A. Polo Rubio1 
2Madrid Hospital Group, Radiation Oncology, Madrid, Spain 
 
Purpose or Objective: The aim of this study was to evaluate 
the acute and late toxicities and disease-specific and overall 
survival after interstitial brachytherapy for the treatment of 
gynecological and digestive tumors.  
 
Material and Methods: A retrospective study was carried out 
on a series of 19 patients referred for interstitial 
brachytherapy in our center between 2008 and 2013 with 
histologically proved locally advanced or recurrent 
gynecological malignancies and digestive tumors. Patients 
with distant metastases were excluded. Treatment consisted 
of brachytherapy alone (5p) (gynecological recurrence and 
anal carcinoma), or after surgery (1p) (rectal carcinoma) or 
after surgery and radiochemotherapy (4p) or after 
radiochemotherapy (9p). The radiochemotherapy with 
cisplatin-based chemotherapy regimens. Previously, 
recurrent patients (4p) were been treated with radiotherapy 
with or without concurrent chemotherapy. Medium dose of 
external beam radiotherapy was 51,7 Gy (range 45-70 Gy) 
followed by interstitial brachytherapy median implant dose 
22,3 Gy (range 9-38,5Gy). Inclusion criteria were as follows: 
Hb minimum 10gm/dl and performance status 70% or more. 
 
Results: Median age was 59 years (range 36-82). With a 
median follow-up of 14 months, local control was achieved 
on clinical examination or magnetic resonance imaging 93,8% 
patients. Among 19 patients studied, 3 lost follow-up and 
they were excluded from late toxicities and survival analysis. 
Eleven of the 19 patients (57,9%) experienced Radiation 
Therapy Oncology Group (RTOG) grade I or II acute toxicities 
proctitis (36,3%), cystitis (81,8%) and ephitelitis (18,2%). Not 
acute toxicities grades 3 or 4 were reported. Two of the 16 
patients (12,5%) experienced RTOG grade I or II late toxicities 
proctitis (6,25%) and cystitis (6,25%). Two of the 16 patients 
(12,5%) experienced RTOG grade III or IV late toxicities rectal 
ulcer (6,25%) and vulvar necrosis (6,25%). Using Kaplan-Meier 
analysis overall survival after minimum follow-up of 14 
months was 93% and disease-free survival was 75% (persistent 
tumor were included in this group). One patient had a 
locoregional recurrence and died of tumor. 
 
Conclusion: Interstitial brachytherapy is a good choice to 
deliver high-dose radiation in gynecological tumor after 
external beam radiotherapy or as an exclusive treatment in 
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recurred and previously radiated digestive tumors. This 
treatment offers adequate locoregional control with 
acceptable range of complications. 
 




Acute toxicity in HDR BT of skin cancer with very high 
viscosity addition silicone custom made molds 
C. Sanz Freire
1Center For Biomedical Research Of La Rioja, Medical Physics 
Department, Logroño, Spain 
1, S. Pérez Echagüen2, G.A. Ossola Lentati2 
2Center For Biomedical Research Of La Rioja, Radiation 
Oncology Department, Logroño, Spain 
 
Purpose or Objective: To study normal skin acute toxicity in 
Non-Melanoma Skin Cancer (NMSC) patients treated with High 
Dose Rate (HDR) Plesiotherapy and very high viscosity 
addition silicone (VHVAS) rubber custom-made molds. VHVAS 
rubber features excellent mechanical and physical properties 
which benefit the stability and reproducibility of the implant. 
On the other hand, the high electron density relative to 
water of these materials will increase the scatter production, 
which may be relevant at the mold-skin interface. 
 
Material and Methods: Our standard applicators are 
polymerized VHVAS molds with catheters embedded. This 
VHVAS model features 99.5% recovery factor after 
compression and maximum 0.20% linear dimensional 
variations. Dosimetric properties of this VHVAS have been 
characterized by our Group elsewhere. Silicone attenuation 
relative to water is <5% up to 3 mm thickness. Maximum 
scatter relative to water measured at the mold interface is 
<14%. Treatment is delivered with a Ir-192 based VARIAN MS 
Gammamed+ HDR unit. All treatments are 3D simulated. A 
sample of 15 Patients with 21 lesions (8 basal cell 
carcinomas, 13 squamous cell carcinomas) representing all 
treated locations were considered. Average age is 83.1 years 
[96-58], 47% without any concomitant diseases and life 
expectancy >5 years. Median lesion area is 5.4 cm2 [1.0-
46.6], treatment depth is 4.0 mm [2-15] and microscopic 
disease margin is 4 mm [2-5]. Standard fractionation is 5.5 
Gy/fr, 10-12 fr, twice a week. Acute toxicity was 
retrospectively assessed following the RTOG criteria. 
 
Results: DVH analysis showed high dose areas having: 
D1cc=8.5 Gy/fr [5.4-14.4], D0.5cc= 9.0 Gy/fr [5.4-16.3], 
D0.1cc= 10.3 Gy/fr [6.2-22.9]. All patients presented 
radiodermatitis 1 month after treatment (G2: 89%, G3: 11%). 
32% presented radiodermatitis at 3 months (G1: 26%, G2: 6%) 
and only one patient presented radiodermatitis G1 at 6 
months. Toxicity score correlation to CTV volume, treatment 
depth, BED prescribed dose, D1cc, D0.5cc and D0,1cc had no 
statistical significance (p>0.05). Treated area was found to 
be predictive of radiodermatitis persistence at 3 months 
after treatment (p=0.036). Lesions located in the legs showed 
longer recovery time from radiodermatitis than other 
locations (4 months vs 1.8 months average). 
 
Conclusion: The use of these VHVAS moulds was well-
tolerated by all patients. Our treatments yield similar results 
to other groups with similar treatment schemes in terms of 
acute toxicity. We can conclude that VHVAS custom made 
molds have a good safety profile. 
 
EP-2016  
A method to transform 2D LDR brachytherapy plans into 
contemporary 3D PDR dose distributions 
E. Rodenburg
1Academic Medical Center / University of Amsterdam, 
Department of Radiation Oncology, Amsterdam, The 
Netherlands 
1, J. Wilkes1, J. Wiersma1, R. Ordoñez 
Marmolejo1, R. Dávila Fajardo1, A. Bel1, B. Pieters1 
 
Purpose or Objective: Formerly in the 2D Low-Dose Rate 
(LDR) era no information about Dose-Volume Histogram (DVH) 
parameters of organs at risk (OARs) was available in 
brachytherapy plans. To enable research on late dose effects 
for children treated with Pulsed-Dose Rate (PDR), 3D dose 
distributions and DVH parameters are required. In this study 
a method was developed to enable calculation of DVH 
parameters. 
 
Material and Methods: Before 2001 pediatric head and neck 
(H&N) patients received LDR brachytherapy as a part of their 
treatment. Of 16 LDR plans (1989-2001) only hard-copy CT 
data, orthogonal x-ray images of the implant and 
documented 2D dose information were available. The 
documented 2D dose information consisted of source 
strength, catheter numbering, catheter loading, and 
treatment time. The hard-copy CT data was digitized, 
transferred to DICOM format and imported in Oncentra 
Brachy (Elekta, v4.3). The visible OARs were delineated and 
used catheters were reconstructed. The Ir192-LDR line 
sources from the original 2D plans were simulated by loading 
the reconstructed catheters with Ir192-PDR source tracks of 
the same length as the LDR sources, with a step size of 
2.5mm. Simulation of a line source dosimetry was necessary 
because the planning system did not support LDR planning. 
All PDR source dwell times were made equal, but scaled to 
the documented 2D dose distribution to obtain the 3D dose 
distribution at time of treatment. Scaling was performed at a 
2D LDR isodose level below 30% of the prescribed dose in a 
plane where the documented 2D dose distribution and 
transformed 3D dose distribution geometrically match. 
Scaling below 30% is done to avoid effects due to the non-
uniform isodose distribution very close to a stepping PDR 
source. To check the reliability of the method the Total 
Reference Air Kerma (TRAK) for both 2D LDR and 3D PDR 
plans were determined and compared. The difference was 
tested with the Wilcoxon Signed Rank Test for paired 
variables. To illustrate the applicability of the method the 
maximum dose, defined as the D0.1cm3, on e.g. chiasm was 
determined. 
 
Results: Of 16 LDR plans 2D data were transformed into 3D 
dose distributions. OARs and DVH parameters of chiasm were 
determined. The mean 2D TRAK was 0.95cGy/1m (IQR 0.89). 
The mean 3D TRAK was 0.89cGy/1m (IQR 0.74). The mean 
difference of 2D TRAK and 3D TRAK was statistically not-
significantly different from 0 (P=0.45). For 7 patients the CT 
data incorporated the chiasm area. The mean chiasm 
maximum dose was 233.6cGy (range 4.6-399.2) using the 
described method. 
 
Conclusion: With the described method it was possible to 
transform 2D LDR brachytherapy plans into a 3D dose 
distribution. This method shows the possibility to use 
information from 2D LDR brachytherapy plans in scientific 
studies in which 3D dose information is needed. 
 
EP-2017  
High dose-rate endoluminal brachytherapy as a treatment 
of primary and recurrent esophageal cancer 
N.H. Nicolay
1Heidelberg University Hospital, Radiation Oncology, 
Heidelberg, Germany 
1,2, J. Wagner1, J. Oelmann-Avendano1, J. 
Debus1,2, P.E. Huber1,2, K. Lindel1 
2German Cancer Research Center, Radiation Oncology, 
Heidelberg, Germany 
 
Purpose or Objective: To evaluate outcomes and toxicities 
after high dose-rate (HDR) endoluminal brachytherapy for the 
treatment of esophageal cancer patients. 
 
Material and Methods: We analyzed the patient records of 36 
patients treated with high dose-rate endoluminal 
brachytherapy for histologically confirmed esophageal 
cancer. Brachytherapy was either applied as a boost 
treatment for definitive radiotherapy and radio-
chemotherapy regimens or as a salvage treatment for 
recurrent tumors. Single radiation doses between 4 and 6 Gy 
were delivered to the endoscopically visible tumor including 
2 cm margins in 2 to 4 sessions. Recurrence-free and overall 
